Youzhiyou Bio-B announced that the company is developing an Aimesalizumab biosimilar drug Y225 to prevent and treat type A hemophilia; its phase I clinical study in China has completed administration of the first patient. The test aims to evaluate the bioequivalence between Y225 and the reference drug Shuyou Lilac® in healthy male subjects.

Youzhiyou Bio-B announced that the company is developing an Aimesalizumab biosimilar drug Y225 to prevent and treat type A hemophilia; its phase I clinical study in China has completed administration of the first patient. The test aims to evaluate the bioequivalence between Y225 and the reference drug Shuyou Lilac® in healthy male subjects.